MindWalk (HYFT) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MindWalk (HYFT) has outperformed MAIA Biotechnology (MAIA) over the past year, losing 23.5% versus a loss of 34.1%. MAIA Biotechnology is the larger company by market cap ($71.0 million vs $67.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYFT | MAIA |
|---|---|---|
| Share price | $1.43 | $1.15 |
| Market cap | $67.37M | $71.00M |
| 1-day change | -4.67% | -2.54% |
| YTD return | -21.43% | -22.88% |
| 1-year return | -23.53% | -34.08% |
| 5-year return | -78.27% | — |
| Forward P/E | — | 1.04 |
| EPS (TTM) | $-0.26 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.99 | $3.19 |
| 52-week low | $0.99 | $0.87 |
| Distance from 52-week high | -52.17% | -63.95% |
| Analyst consensus | none | none |
| Avg. price target upside | +202.80% | +943.48% |
| Average volume | 225.20K | 527.89K |
| Shares outstanding | 47.11M | 61.74M |
| Employees | 74 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HYFT has outperformed MAIA by 10.5 percentage points over the past year.
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Healthcare · Biotechnology · 74 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Healthcare · Biotechnology · 13 employees
HYFT vs MAIA FAQ
Which is bigger, MindWalk or MAIA Biotechnology?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $71.00M compared with $67.37M for MindWalk (HYFT).
Which stock has performed better over the past year, HYFT or MAIA?
HYFT returned -23.53% over the past 12 months, compared with -34.08% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are MindWalk and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.